Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Ikeda, Takashi  [Clear All Filters]
2024
Oyama T, Fujiwara S-I, Tominaga R, Yokoyama D, Noguchi A, Furuki S, Koyama S, Murahashi R, Nakashima H, Hyodo K, et al. Effects of CD34 cell dose on engraftment and long-term outcomes after allogeneic bone marrow transplantation. Clin Transplant. 2024;38(4):e15313.
Nakano H, Sato K, Izawa J, Takayama N, Hayakawa H, Ikeda T, Kawaguchi S-I, Mashima K, Umino K, Morita K, et al. Fatty Acids Play a Critical Role in Mitochondrial Oxidative Phosphorylation in Effector T Cells in Graft-versus-Host Disease. Immunohorizons. 2024;8(3):228-241.
2023
Nagayama T, Fujiwara S-I, Tominaga R, Yokoyama D, Noguchi A, Furuki S, Oyama T, Koyama S, Murahashi R, Nakashima H, et al. Early reversal of the lymphocyte-to-monocyte ratio after allogeneic-hematopoietic stem cell transplantation is associated with reduced relapse and improved prognosis. Clin Transplant. 2023:e15116.
Iemura T, Kondo T, Ueda A, Maeda T, Kitawaki T, Arai Y, Kanda J, Ikeda T, Imada K, Ishikawa T, et al. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan. Ann Hematol. 2023.
Suzuki K, Shimazu Y, Minakata D, Ikeda T, Takahashi H, Tsukada N, Kanda Y, Doki N, Nishiwaki K, Miwa A, et al. Efficacy of autologous stem cell transplantation for patients with myeloma having suboptimal response: A multicenter retrospective analysis. Transplant Cell Ther. 2023.
Morita-Fujita M, Shindo T, Iemura T, Arai Y, Kanda J, Okada K, Ueda Y, Yoshiyuki O, Anzai N, Mori T, et al. Epitope mismatch at HLA-DRB1 associates with reduced relapse risk in cord blood transplant for standard-risk hematological malignancy. Transplant Cell Ther. 2023.
Ikeda T, Sato K, Kawaguchi S-I, Izawa J, Takayama N, Hayakawa H, Umino K, Morita K, Matsumoto K, Ushijima K, et al. Forodesine Enhances Immune Responses through Guanosine-Mediated TLR7 Activation while Preventing Graft-versus-Host Disease. J Immunol. 2023.
Hayashi H, Iwasaki M, Nakasone H, Tanoshima R, Shimabukuro M, Takeda W, Nishida T, Kako S, Fujiwara S-I, Katayama Y, et al. Impact of stem cell selection between bone marrow and peripheral blood stem cells for unrelated hematopoietic stem cell transplantation for hematologic malignancies: on behalf of the Donor/Source Working Group of the Japanese Society for Transplantation a. Cytotherapy. 2023.
Wada F, Kanda J, Kamijo K, Nishikubo M, Yoshioka S, Ishikawa T, Ueda Y, Akasaka T, Arai Y, Izumi K, et al. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation. Cell Transplant. 2023;32:9636897231194497.
2021
Nishikori M, Masaki Y, Fujii N, Ikeda T, Takahara-Matsubara M, Sugimoto S, Kondo E. An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. Int J Hematol. 2021.
Yasui K, Enami T, Okamura-Shiki I, Ueda T, Fukushima K, Matsuyama N, Kimura T, Takanashi M, Hosen N, Ikeda T, et al. Passive immune basophil activation test for the identification of allergic episodes from various adverse events elicited by haematopoietic cell transplantation: A pilot study. Vox Sang. 2021.
Iida S, Izumi T, Komeno T, Terui Y, Chou T, Ikeda T, Berg D, Fukunaga S, Sugiura K, Sasaki M. A phase 2, open-label, multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma. Int J Clin Oncol. 2021.
Minakata D, Fujiwara S-I, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi S-I, Toda Y, Ito S, Nagayama T, et al. Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis. Leuk Res. 2021;112:106750.
2019
Ikeda T, Mori K, Kawamura K, Mori T, Hagiwara S, Ueda Y, Kahata K, Uchida N, Tsukada N, Murakami S, et al. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. Hematol Oncol. 2019.
Kondo E, Ikeda T, Izutsu K, Chihara D, Shimizu-Koresawa R, Fujii N, Sakai T, Kondo T, Kubo K, Kato Y, et al. High dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: Data from the Japan Society for Hematopoietic Cell Transplantation (JSHCT) registry. Biol Blood Marrow Transplant. 2019.
Fujiwara S-I, Ikeda T, Morita K, Shinzato T, Ishikawa N, Nakamura N, Yagisawa T, Kanda Y. Multiple myeloma derived from a kidney transplant donor who also developed myeloma after kidney donation. Am J Transplant. 2019.
2018
Itonaga H, Ota S, Ikeda T, Taji H, Amano I, Hasegawa Y, Ichinohe T, Fukuda T, Atsuta Y, Tanizawa A, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. Leuk Res. 2018;75:50-57.
2016
Nakasu Y, Mitsuya K, Hayashi N, Okamura I, Mori K, Enami T, Tatara R, Nakasu S, Ikeda T. Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study. Springerplus. 2016;5:307.